Concepedia

Ian L. Dale

IL

23

Publications

1K

Citations

19

H-Index

1982

Active since

Affiliations

AstraZeneca (United Kingdom)(Current)

AstraZeneca (United States)

AstraZeneca (Sweden)

Aston University

Wellcome Centre for Cell-Matrix Research

Ian L. Dale is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and drug discovery.

Top concepts

Publications per year

1982–2024

23

Publications

23

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao et al. · Molecular Cancer Therapeutics · 2016 · 147 citations · Full text

, , +17

Potent and selective bivalent inhibitors of BET bromodomains

Michael J. Waring, Huawei Chen, Alfred A. Rabow et al. · Nature Chemical Biology · 2016 · 134 citations · Full text

, , +3

Assessment of Cardiomyocyte Contraction in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes

Amy Pointon, Alexander R. Harmer, Ian L. Dale et al. · Toxicological Sciences · 2014 · 102 citations · Full text

Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells

Ian L. Dale, Andreas J. Gescher · International Journal of Cancer · 1989 · 59 citations

An evaluation of fluorescence polarization and lifetime discriminated polarization for high throughput screening of serine/threonine kinases

Ann Fowler, Denise Swift, Emma Longman et al. · Analytical Biochemistry · 2002 · 53 citations

, , +11

Rows per page

1–5 of 23